Skip to content
DataLookout
Menu

NCT04775082

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

StatusActive, Not Recruiting
PhasePhase 3
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 53 versions: 39 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 16, 2026 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 9 words
    • Enrollment target: estimated 78 to confirmed 82
    • Secondary endpoints: 11 to 12
    • Site details revised at 5 of 32 sites
    • Publications: details revised at 1 of 1 entry
  2. Minor Study sites: 31 to 32
    • Study completion date: Jan 15, 2027 to Feb 8, 2027
    v51
  3. Minor Study sites: 28 to 31v50
  4. Minor Study sites: 29 to 28v49
  5. Minor Study sites: 26 to 29v48
Show 34 earlier versionsHide 34 earlier versions
  1. Minor Publications: details revised at 1 of 1 entryv47
  2. Minor Study sites: 27 to 26v44
  3. Minor Study sites: 26 to 27v43
  4. Minor Study sites: 25 to 26v40
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 27 to 25
    • Primary completion date changed from estimate of Jul 7, 2023 to Aug 1, 2023
    • Study completion date: Jan 18, 2024 to Jan 15, 2027
    v38
  6. Minor Site details revised at 2 of 27 sitesv35
  7. Notable Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 26 to 27
    v34
  8. Minor Study completion date: Jan 4, 2024 to Jan 18, 2024
    • Site details revised at 11 of 26 sites
    v32
  9. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 26 of 26 sites
    v30
  10. Minor Site details revised at 4 of 26 sitesv28
  11. Minor Site details revised at 1 of 26 sitesv27
  12. Minor Site details revised at 1 of 26 sitesv26
  13. Minor Study sites: 25 to 26v25
  14. Minor Site details revised at 2 of 25 sitesv24
  15. Minor Site details revised at 1 of 25 sitesv23
  16. Minor Study sites: 24 to 25v22
  17. Minor Site details revised at 1 of 24 sitesv21
  18. Minor Site details revised at 1 of 24 sitesv20
  19. Minor Site details revised at 1 of 24 sitesv19
  20. Minor Site details revised at 1 of 24 sitesv18
  21. Minor Study sites: 23 to 24v17
  22. Minor Site details revised at 1 of 23 sitesv16
  23. Minor Site details revised at 1 of 23 sitesv15
  24. Minor Site details revised at 1 of 23 sitesv14
  25. Minor Study sites: 22 to 23v13
  26. Minor Site details revised at 1 of 22 sitesv12
  27. Minor Study sites: 21 to 22v11
  28. Minor Site details revised at 2 of 21 sitesv10
  29. Minor Study sites: 19 to 21v9
  30. Minor Study sites: 17 to 19v8
  31. Minor Study sites: 16 to 17v7
  32. Minor Study sites: 13 to 16v6
  33. Minor Study sites: 12 to 13v5
  34. Minor Study sites: 11 to 12v4
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Relative Change in Body Mass Index (BMI)
Timeframe: Baseline (week 0), week 56

Secondary (12)

Relative Change in Body Weight (Percentage)
Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI
Change in Body Weight (Kilogram)
Change in BMI Standard Deviation Score (WHO.Int)
Percentage of Participants Achieving ≥10% Reduction of BMI
Show 7 moreShow less
Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])
Change in Waist Circumference
Change in Systolic Blood Pressure
Change in Diastolic Blood Pressure
Change in Glycated Haemoglobin (HbA1c)
Treatment Emergent Adverse Events (TEAEs)
Treatment Emergent Serious Adverse Events (SAEs)

Arms and interventions

Liraglutide 3.0 mgExperimental

The treatment duration is 56 weeks and the follow-up period is 26 weeks.

PlaceboPlacebo comparator

The treatment duration is 56 weeks and the follow-up period is 26 weeks.

Drugs: Liraglutide, Placebo

Sites

32 sites in 9 countries

United States 9, Portugal 8, Russia 4, Belgium 2, India 2, Israel 2, Malaysia 2, Switzerland 2, Mexico 1